Valeant Pharmaceuticals to Acquire Bausch + Lomb For $8.7 Billion

News   May 29, 2013

 
Valeant Pharmaceuticals to Acquire Bausch + Lomb For $8.7 Billion
 
 
 

RELATED ARTICLES

Symmetry-breaking Method Opens Way for Bioactive Compounds

News

EPFL chemists have developed a new catalytic method for symmetry breaking. Published in Angewandte Chemie, the method can help synthesize important building blocks for bioactive compounds such as anticancer drugs.

READ MORE

Scientists Report The Development of a Potent New Medicine to Fight Addiction

News

Scientists report the development of a potent new medicine to fight addiction.

READ MORE

Minoryx Therapeutics spins off SEE-Tx platform into new company, Gain Therapeutics

News

The new Swiss company will operate in Lugano and Barcelona under the scientific management of Minoryx co-founder Dr Xavier Barril.

READ MORE

 

Comments | 0 ADD COMMENT

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE